INVESTMENT OPPORTUNITY

Medical Need


Neurodegenerative diseases:
   No cure or impactful treatments available
   Multibillion $ healthcare burden
Focus on ALS:
Rapid progression to full paralysis and death
500.000 patients worldwide
No impactful treatment

Technology


Small molecule regenerative technology
RNAi-based technology platform
Therapeutic modulation through modulation
  of a key pathway and gene-silencing for
  neurodegenerative damage
Mechanism of action/target of primary
  effect characterized
Successful pre-clinical proof of concept (PoC)
Synergic therapeutic approach

Investment Return


Dynamic valuation strategy
Probability of success based on
  uniquely positive animal PoC
Promising opportunities for short-
  to mid-term return of investment

Market


Growing prevalence of neurodegenerative
  diseases in elderly population
Orphan drug pricing structure:
   market size:
    $1.1 B for ALS (ww)
    $3.8 B for TBI (USA)
Increase disease awareness and rate of
  diagnosis (ALS):
  Global ALS drugs market to grow at a
    CAGR of 5.39% over 2013-2019

REQUEST INVESTORS PACKAGE